Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in the treatment of diabetic kidney disease: a meta-analysis

Key Points

• Beneficial effects in diabetic kidney disease patients were confirmed, with significant health improvements noted.
• The analysis shows an increased risk of genital infections and diabetic ketoacidosis, particularly in SGLT2 inhibitor users.
• Conducted as a meta-analysis, this study synthesizes data from various trials to assess treatment effects.
• This analysis highlights the need for careful monitoring due to the associated risks with SGLT2 inhibitors.